在复发/难治性外周 T 细胞淋巴瘤中，如果根据 CD30 阳性使用异环磷酰胺、卡铂和依托泊苷联合 Brentuximab vedotin 或 Romidepsin。
Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.
机构信息
Houston Methodist Cancer Center, Houston, Texas, USA.
Houston Methodist Hospital, Houston, Texas, USA.
出版信息
Cancer Rep (Hoboken). 2022 Jul;5(7):e1581. doi: 10.1002/cnr2.1581. Epub 2022 Mar 8.
BACKGROUND
Relapsed/refractory peripheral T-cell lymphoma (R/R PTCL) has a poor prognosis. Romidepsin (Ro) and brentuximab vedotin (Bv), combined with ifosfamide, carboplatin, and etoposide (ICE) has not been significantly studied in PTCL.
AIM
We report outcomes of Bv-ICE in CD30 (+) and Ro-ICE in CD30 (-) R/R PTCL treated in "Blinded for peer review" Cancer Center.
METHODS AND RESULTS
We retrospectively identified R/R PTCL patients treated with BV-ICE or romidepsin-ICE from May 2016 to September 2019. Out of 13 R/R PTCL patients, 6 were treated with Bv-ICE and 7 with Ro-ICE. Bv-ICE had an overall response rate (ORR) of 66.7%, with all the patients achieving a complete response. ORR was 71.4% for Ro-ICE with 57.1% of patients achieving a complete response. Two patients treated with Bv-ICE and three treated with Ro-ICE received transplantation.
CONCLUSION
In our experience, treatment with Bv-ICE and Ro-ICE based on CD30 positivity is feasible and effective to treat patients with R/R PTCL.
背景
复发/难治性外周 T 细胞淋巴瘤（R/R PTCL）预后不良。罗米地辛（Ro）和 Brentuximab vedotin（Bv）联合异环磷酰胺、卡铂和依托泊苷（ICE）在 PTCL 中的研究尚未得到充分证实。
目的
我们报告了在“同行评审盲法”癌症中心中，CD30(+)的患者接受 Bv-ICE、CD30(-)的患者接受 Ro-ICE 治疗的结果。
方法和结果
我们回顾性地确定了 2016 年 5 月至 2019 年 9 月期间接受 BV-ICE 或罗米地辛 ICE 治疗的 R/R PTCL 患者。在 13 名 R/R PTCL 患者中，6 名接受了 Bv-ICE 治疗，7 名接受了 Ro-ICE 治疗。Bv-ICE 的总体缓解率（ORR）为 66.7%，所有患者均达到完全缓解。Ro-ICE 的 ORR 为 71.4%，57.1%的患者达到完全缓解。2 名接受 Bv-ICE 治疗的患者和 3 名接受 Ro-ICE 治疗的患者接受了移植。
结论
根据 CD30 阳性情况，我们的经验表明，Bv-ICE 和 Ro-ICE 治疗 R/R PTCL 是可行且有效的。
Zotero 插件